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Introduction: Anaplastic lymphoma kinase (ALK) gene rearrange-
ment characterizes a subgroup of patients with lung adenocarcinoma 
who may benefit from ALK inhibitors. Fluorescence in situ hybrid-
ization (FISH) with a break-apart/split-signal strategy is the gold 
standard to investigate ALK. The cutoff to define ALK positivity has 
been settled at 15% or greater. A subset of patients has ALK border-
line status, showing 15% ± 5% positive cells. Several aspects, both 
biological and technical, might influence signals evaluation, making 
FISH interpretation a challenging task. To improve ALK evaluation, 
we classified the different FISH patterns on the basis of the type of 
the split signals, namely short, long, far away, and deleted.
Methods: We investigated ALK gene status by FISH in 244 lung 
adenocarcinomas and in a series of ALK negative cell lines samples, 
collected in three Institutions.
Results: ALK positive profile was found in 12% of patients; long, 
deleted, and far-away splits were the primary patterns observed. 
ALK borderline profile characterized 10% of samples; long and 
deleted splits were significantly more frequent in those borderline 
finally classified as ALK positive, whereas short split were mostly 
detected in those borderline patients finally classified as ALK nega-
tive (p = 3.4 × 10−3). In the ALK negative control series, short split 
was the predominant pattern. Concordance was observed among dif-
ferent operators and probes for both samples and controls.
Conclusions: Difficulties in ALK FISH signal interpretation might 
be bypassed using this detailed scoring system, which is highly 
reproducible, helps clarify borderline samples (according to split 
type), and provides experimental evidence that 15% is a reasonable 
cutoff to overcome the assay-dependent background noise.
Key Words: ALK, Fluorescence in situ hybridization, ALK inhibitor, 
Lung cancer.
(J Thorac Oncol. 2015;10: 595–602)
The introduction of new treatments targeting specific molecular markers is quickly growing, and oncologists, 
pathologists, and scientists must keep up with new molecular 
tests to determine the most appropriate options for patients. 
A clear example is represented by crizotinib (PF-02341066; 
Pfizer Labs, Division of Pfizer Inc., New York, NY), a tyrosine 
kinase (TK) inhibitor, which was very recently approved for 
the treatment of patients with lung adenocarcinoma (ADC) 
harboring anaplastic lymphoma kinase (ALK) gene rearrange-
ment.1–4 ALK encodes a TK receptor normally expressed only 
in selected neuronal cell types.5 In lung ADCs, the ALK gene 
(2p23) is principally deregulated by a small paracentric inver-
sion (12-Mb long) on the short arm of chromosome 2, with 
or without an interstitial deletion, that leads to the fusion of 
the N-terminal half of the echinoderm microtubule-associated 
protein-like 4 (EML4) gene (2p21) to the TK portion of ALK, 
resulting in a chimeric TK protein with oncogenic activity.6 
More than 10 EML4-ALK variants have been identified, and 
other interchromosomal fusion partner genes, such as TRK-
fused gene (TFG, located in 3q12.2) and kinesin family mem-
ber 5B (KIF5B, located in 10p11.22), have been reported.7
Although different methods are used to detect ALK 
deregulations,8–11 fluorescence in situ hybridization (FISH) 
still represents the gold standard, revealing every type of rear-
rangement occurring in the ALK TK domain, whether it is an 
interchromosomal or intrachromosomal translocation, inde-
pendently from the partner gene involved.12 Various types of 
FISH probes are commercially available to investigate ALK 
gene status, but the break-apart/split-signal strategy is consid-
ered the most suitable approach.13,14
Although reported as an infrequent event in lung ADCs 
(<10%),6,15,16 the detection of ALK gene rearrangements by 
FISH has strongly become a routine predictive tool for thera-
peutic decisions. Despite the proposal of general recommen-
dations17,18 and the establishment of an international quality 
assurance scheme,19 some technical aspects, mainly related to 
the type of the rearrangement (principally an inversion) and 
the type of investigated sample (lung cancer), render ALK 
FISH interpretation extremely challenging. Initial FISH stud-
ies defined a cutoff of 15% cells or greater with ALK rear-
rangement to classify patients as ALK positive (ALK+) and, 
therefore, eligible for crizotinib treatment.13,20 Recently, the 
same authors identified a subset of borderline patients who 
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might benefit from this therapy, and they wondered whether 
this cutoff actually reflects a biological distinction between 
ALK+ and ALK negative (ALK−) tumors.21
To better understand these issues, we evaluated the ALK 
FISH test on a multicenter cohort of 244 lung ADC samples 
using a tailored detailed scoring system for FISH interpreta-
tion. We also investigated a control panel of ALK− cell lines 
to assess how the technical and methodological limits of this 
assay may impact the cutoff definition.
PATIENTS AND METHODS
Patient Population
A series of 244 lung ADCs were examined from three 
participating Institutions from November 2011 to July 2013. 
Ninety-one cases were collected at the Institute of Pathology 
of Locarno (Switzerland), 120 cases at the Department of 
Pathology of Varese (Italy), and 33 cases at the Department 
of Pathology of Brescia (Italy). All patients received ALK 
FISH test after the request of their oncologists. In almost all 
the cases (230 of 244, 94%), EGFR gene mutation analysis 
(exons 18–21) was performed for clinical purposes, following 
the standard protocol for DNA extraction and sequencing, as 
previously described.22,23 EGFR results were evaluable in 215 
cases (215 of 230, 93%).
Each case was centrally reviewed to confirm the histo-
pathologic assessment and verify the proper content of tumor 
cells. This study was approved by the institutional review 
boards of each participating center.
ALK FISH Probes
ALK gene rearrangement was investigated using the 
FDA-approved ALK break-apart probe by Abbott (Abbott 
Vysis ALK Break Apart FISH Probe Kit; Abbott Molecular, 
Abbott Park, IL) in 123 lung ADCs and the ALK split-signal 
probe by Dako (ALK FISH DNA Probe; Split Signal, Dako, 
Denmark) in 121 lung ADCs. These probes have both a dual-
color strategy, being realized to flank the ALK breakpoint 
cluster regions with red and green signals. Designs, maps, and 
dimensions of probes hybridizing ALK-downstream sequence 
(in red) and ALK-upstream sequence (in green) are com-
pletely similar, resulting in identical signals when evaluated 
at fluorescence microscope. When ALK gene is maintained, 
the probes are visualized by a fused red and green spot; in 
contrast, when a disruption occurs in the ALK sequence, the 
red and green signals split and can be visualized separately 
(split pattern).
These two ALK FISH probes were validated in a sub-
group of 33 lung ADCs for which a single operator inves-
tigated two consecutive slides hybridized with the Abbott 
ALK probe and the Dako ALK probe, respectively. The rate 
of association between the two probes was evaluated using 
the Spearman rank correlation coefficient (SAS System; SAS 
Institute Inc., Cary, NC).
FISH Testing
FISH was performed on 199 histological sections (4-μm 
thick) from formalin-fixed paraffin-embedded (FFPE) tissue 
blocks and on 45 cytological specimens following the manu-
facturer’s instructions. Histological samples included both 
biopsies (105 of 199, 53%) and tumor resection samples (94 of 
199, 47%). Cytological samples included cell blocks (29 of 45, 
64%), conventional smears (12 of 45, 27%), and thin-layer prep-
arations (4 of 45, 9%). In patients for whom cytological fresh 
material was not available (12 cases), Papanicolaou-stained 
slides were retrieved from the archive and used for FISH.
In addition to samples of lung ADC patients, ALK FISH 
was performed on 16 commercial slides from ALK− lung cell 
lines, realized as FFPE sections from cell blocks (ProbeCheck 
ALK negative Control Slides; Abbott Molecular). These slides 
were sheared among the three operators for ALK FISH scor-
ing. A total of 48 independent readings were obtained and 
used to constitute the panel of controls. Here, the cutoff point 
was calculated as the mean (M) value plus 3 SDs of nuclei 
showing ALK split signals; the SD was calculated assuming a 
binomial distribution of the spots.
ALK FISH Pattern Scoring System
ALK evaluation was performed following literature rec-
ommendations,17 improved by a detailed registration of all the 
FISH patterns observed, in particular, the split one, for which 
the length of the split is described.
Specifically, ALK FISH patterns are qualified as follows: 
(1) fused (ALK_F) if the red and green signals are very close 
or overlapped (Fig. 1A); (2) short split (ALK_S) if the red and 
green signals are visualized as clearly separated spots but their 
distance is equal to 2 diameters of the signals (Fig. 1B); (3) 
long split (ALK_L) if the red and green signals are visualized 
as effectively separate spots and their distance is between 2 
and 3 signal diameters (Fig. 1C); (4) far-away split (ALK_FA) 
if the red and green signals are visualized as opposite spots 
and their distance is greater than 3 diameters (Fig. 1D); v) 
deleted split (ALK_D) if the green signal (ALK-upstream 
sequence) is missing (Fig. 1E). In case of cells showing mul-
tiple split, the longer pattern is the one recorded.
The ALK_F pattern represents a normal ALK allele. 
In contrast, ALK_S and ALK_L are suggestive of an intra-
chromosomal translocation/inversion, ALK_FA indicates an 
interchromosomal translocation, and ALK_D signifies an 
intrachromosomal translocation/inversion followed by a dele-
tion.17 Altogether, cells with ALK_S, ALK_L, ALK_FA splits, 
and ALK_D constitute the pattern of ALK-rearranged cells 
(ALK_R). A patient was defined as ALK+ when the ALK_R 
population was detected in 15% of tumor cells or greater.17
The number of ALK_F signals, visualized alone or in 
combination with ALK rearrangements, was also recorded. 
Following recently published criteria,24 ALK polysomy was 
defined when three or greater ALK alleles (including both nor-
mal and rearranged ones, see Figs. 1F and D, respectively) 
were found in 30% or greater of the cells. ALK polysomy 
was used as surrogate marker for the presence of an adequate 
number of neoplastic cells in cases of small biopsies or poor 
material. ALK gene amplification, confirmed with centro-
meric probe of chromosome 2, was identified as the presence 
of more than 6 clustered red-green fused signals in 10% or 
greater of cells.24
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ALK FISH Evaluation
A minimum of 100 morphologically clear, nonoverlap-
ping nuclei from at least eight to 10 areas were scored for each 
tumor. In the case of small biopsies, the minimum considered 
for interpretation was 50 cells. In the ALK− control panel, 
between 100 and 500 cells per slide were scored. Only experi-
ments with at least 90% hybridization efficiency were consid-
ered. Signals evaluation was performed independently in each 
laboratory. Interobserver reproducibility was assessed on con-
trol slides that were shared among the three Institutions. The 
Spearman rank correlation coefficient was used to evaluate the 
rate of association (SAS System). One third of lung ADC cases 
were randomly selected and shared among the three opera-
tors to check their final FISH classification (ALK+ or ALK−), 
giving superimposed results. Each of the three Institutions 
involved in this study have 10 years of experience in solid 
tumors FISH evaluation and participated in the ALK Quality 
Assessment programs organized by the European Society of 
Pathology (European Society of Pathology lung external qual-
ity assessment scheme, 2012 and 2013)19 and by the Italian 
Society of Pathology and Oncology (Associazione Italiana di 
Oncologia Medica e Società Italiana di Anatomia Patologica 
[AIOM-SIAPEC] external quality assessment scheme for ALK 
rearrangement in lung ADCs, 2012 and 2013).25
All FISH experiments were manually scored by conven-
tional fluorescence microscope.
A digital tool for imagine analysis (Bioview Duet 
System; BioView Ltd., Rehovot, Nes Ziona, Israel) was 
applied only on selected cases to scale FISH signals and split 
dimensions, only for confirmatory and descriptive purposes.
ALK Protein Immunohistochemical Staining
ALK protein status was investigated in selected FFPE 
cases by immunohistochemistry (IHC) using the monoclonal 
antibody D5F3 (Ventana Medical System, Tucson, AZ) with 
tyramide amplification step, following the manufacturer’s proto-
col. Specimens were scored IHC positive if intense cytoplasmic 
staining was present. Cases were scored IHC negative if there 
was no or only weak cytoplasmic positivity.
Commercial FFPE sections from cell blocks of ALK+ 
and ALK− lung cancer cell lines (ProbeCheck ALK-positive and 
ProbeCheck ALK-negative Control Slides; Abbott Molecular) 
were used as positive and negative controls, respectively.
RESULTS
Patient Characteristics
The investigated cohort of 244 patients included 141 
(58%) males and 103 (42%) females. The median age was 65 
years (range, 30–92 years).
An EGFR gene mutation was found in 11 of evaluable 
cases (11 of 215, 5%). Among EGFR-mutated tumors, seven 
(64%) showed a deletion in exon 19 (codons E746-A750), 
one (9%) had a mutation in exon 20 (S784P), two (18%) 
had a mutation in exon 21 (L858R and T847I), and one (9%) 
had concomitant mutations in exons 20 and 21 (T790M and 
L858R, respectively).
ALK FISH Probe Validation
ALK Abbott and ALK Dako probes gave concordant 
results and were strongly correlated in detecting the rate of 
ALK_R cells (r = 0.60, p = 0.002) in the 33 lung ADC cases 
hybridized with both probes (see Supplementary Figure S1, 
Supplemental Digital Content, http://links.lww.com/JTO/
A763). A correlation was also observed for subclasses of 
ALK_S cells (r = 0.38, p = 0.0305) and ALK_L cells (r = 0.51, 
p = 0.0023) (see Supplementary Table S1, Supplemental 
Digital Content, http://links.lww.com/JTO/A763).
Comparison among Three Operators
After qualifying more than 1700 cells from the same 
negative control slides, the three operators (A, B, and C) pro-
duced concordant results and were strongly correlated in the 
detection of the rate of ALK_R cells (A versus B: r = 0.87, 
p = 0.33; A versus C: r = 0.87, p = 0.33; B versus C: r = 1.00, 
p < 0.0001) (see Supplementary Figure S2, Supplemental 
Digital Content, http://links.lww.com/JTO/A763). Similar 
correlations were observed for ALK_S (A versus B: r = 0.50, 
p = 0.67; A versus C: r = 0.50, p = 0.67; B versus C: r = 1.00, 
p < 0.0001), ALK_L (A versus B: r = −1.00, p < 0.0001; A 
versus C: r = 1.00, p < 0.0001; B versus C: r = −1.00, p < 
0.0001), ALK_FA (A versus B: r = 1, p < 0.0001; A versus 
FIGURE 1. ALK FISH pattern scoring 
system. A, Normal cells showing two 
ALK-fused signals (ALK_F); (B) ALK 
short split pattern (ALK_S); (C) ALK 
long split pattern (ALK_L); (D) ALK 
far-away split pattern (ALK_FA); (E) 
ALK-deleted split pattern (ALK_D). 
Cells positive for ALK rearrangement 
(ALK_R) are those showing short, 
long, far-away splits, and deleted 
patterns; (F) ALK polysomy. ALK, 
anaplastic lymphoma kinase; FISH, 
fluorescence in situ hybridization.
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C: r = 0.87, p = 0.33; B versus C: r = 0.87, p = 0.33), and 
ALK_D (A versus B: r = 1, p < 0.0001; A versus C: r = 0.50, 
p = 0.67; B versus C: r = 0.50, p = 0.67) (see Supplementary 
Table S2, Supplemental Digital Content, http://links.lww.
com/JTO/A763).
ALK FISH Results on Lung ADC Patients
Overall, the FISH analysis was successful in 232 ADCs 
(95%) and failed in 12 ADCs (5%). The rate of inadequacy 
was 3% for resection, 6% for biopsies, and 7% for cytological 
samples. Overall, of the nonevaluable lung ADC samples, half 
were biopsies.
In the entire cohort of 232 lung ADCs, the percentage of 
ALK_R cells ranged from 0% to 100% (Fig. 2), with varying 
frequencies of the different split patterns (see Supplementary 
Figure S3 and Table S3, Supplemental Digital Content, http://
links.lww.com/JTO/A763, for details).
Twenty-eight cases were classified as ALK+ (12%). The 
rate of ALK+ lung ADCs was similar among the three par-
ticipating Institutions (12%, 13%, and 9%, respectively). The 
ALK+ cases were equally distributed among cytological speci-
mens (17%), biopsies (13%), and resections (9%).
In ALK+ ADCs (28 cases), different frequencies of 
cells populations carrying all split patterns were observed 
(Fig. 3 and Supplementary Table S4, Supplemental Digital 
Content, http://links.lww.com/JTO/A763). Considering the 
prevalent one, nine (32%) cases were characterized by the 
long split pattern, 10 (36%) by the deleted split, one (3%) by 
the far-away split, and eight (29%) by the short split pattern 
(see Supplementary Table S4, Supplemental Digital Content, 
http://links.lww.com/JTO/A763). Overall, 20 (71%) ALK+ 
ADCs carried a “nonshort” split as the prevalent pattern 
(see Supplementary Table S9, Supplemental Digital Content, 
http://links.lww.com/JTO/A763).
Among the ALK+ cases, 22 (79%) had a total ALK_R 
population rate clearly over the cutoff value, with greater 
than 20% of rearranged cells. These cases were called frank 
ALK+ samples, and 15 of these (68%) were characterized 
by a prevalent nonshort split type. The remaining six (21%) 
ALK+ cases had an ALK_R population rate close to the cut-
off value, with 15% to 20% of rearranged cells. These cases 
were defined as borderline ALK+; all except one (five of six, 
83%) of borderline ALK+ cases carried a nonshort split type 
as the dominant one (see detailed frequencies of ALK_R 
cells in Fig. 4 and in Table S5; incidence of split types in 
Supplementary Table S9, Supplemental Digital Content, 
http://links.lww.com/JTO/A763).
Two hundred four (88%) ADCs were classified as ALK−. 
Excluding 17 cases (8%) for which no prevalent split popula-
tion was observed, the dominant pattern was the short split in 
152 (81%), the long split in 23 (12%), and the deleted in 12 
(6%) cases (Supplementary Tables S6 and S9, Supplemental 
Digital Content, http://links.lww.com/JTO/A763).
Among the ALK− cases, 187 (92%) had a total ALK_R 
population rate clearly under the cutoff value, with less 
than 10% of rearranged cells. The majority of these cases, 
globally called frank ALK−, showed a prevalent short split 
FIGURE 2.  ALK_R cells distribution in lung ADCs (n = 232). 
ALK_R: ALK-rearranged cells (namely all cells with positive 
patterns, constituted by ALK_S+ALK_L+ALK_FA+ALK_D). ALK, 
anaplastic lymphoma kinase; ADC, adenocarcinoma.
FIGURE 3. ALK FISH patterns distribution in ALK+ lung 
ADCs (n = 28). ALK_R: ALK-rearranged cells (namely all cells 
with positive patterns, constituted by ALK_S+ALK_L+ALK_
FA+ALK_D); ALK_S: ALK+ cells with a short split; ALK_L: ALK+ 
cells with a long split; ALK_FA: ALK+ cells with a far-away 
split; ALK_D: ALK+ cells with a deleted pattern. ALK, anaplastic 
lymphoma kinase; ADC, adenocarcinoma; FISH, fluorescence 
in situ hybridization.
FIGURE 4. ALK FISH patterns distribution in ALK borderline 
lung ADCs (n = 23); ALK borderline patients have an ALK_R 
population in a range of 10–20% ALK_R: ALK-rearranged 
cells (namely all cells with positive patterns, constituted by 
ALK_S+ALK_L+ALK_FA+ALK_D); ALK_S: ALK+ cells with a 
short split; ALK_L: ALK+ cells with a long split; ALK_FA: ALK+ 
cells with a far-away split; ALK_D: ALK+ cells with a deleted 
pattern. ALK, anaplastic lymphoma kinase; ADC, adenocarci-
noma; FISH, fluorescence in situ hybridization.
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type (81%). The remaining 17 (8%) had an ALK_R popula-
tion rate close to the cutoff value, with 10% to 15% of rear-
ranged cells. These cases were defined as borderline ALK−, 
and all except two (88%) carried the short split type as the 
dominant pattern (see detailed frequencies of ALK_R cells 
in Fig. 4 and in Supplementary Table S5; incidence of split 
patterns in Supplementary Table S9, Supplemental Digital 
Content, http://links.lww.com/JTO/A763).
Considering the predominant split type (short versus 
nonshort), significant differences were observed between 
ALK+ and ALK− patients (p = 5 × 10−8, two-tailed Fisher’s 
exact test), between frank ALK+ and frank ALK− patients 
(p = 6.1 × 10−6), between borderline ALK+ and borderline 
ALK− patients (p = 3.4 × 10−3). Borderline ALK+ patients were 
characterized by a prevalent nonshort split pattern, similarly 
to frank ALK+ patients (p = 0.64); in contrast, borderline 
ALK− patients were characterized by a prevalent short split 
type, similarly to frank ALK− patients (p = 0.74) (see Table 1 
for details).
Overall, ALK borderline ADCs (those with 10–20% 
ALK_R cells) represented 10% (23 of 232) of the entire 
cohort of patients (Fig. 4).
ALK polysomy was observed in 77% of the investigated 
ADCs, in both ALK+ and ALK− cases, with a frequency of 
61% (17 of 28 ALK+) and of 79% (161 of 204 ALK−), respec-
tively. ALK polysomy showed a strong trend of correlation 
with an ALK− profile (p = 0.053, two-tailed Fisher’s exact 
test) (see Supplementary Table S7, Supplemental Digital 
Content, http://links.lww.com/JTO/A763). ALK gene ampli-
fication was observed in 5% of cases (two ALK+ and nine 
ALK−). In these tumors, amplified cells never constituted the 
major neoplastic clone (frequency of amplified cells ranged 
from 10% to 30%) but were always found as intermingled to 
cells carrying ALK polysomy.
Correlation between ALK FISH and ALK 
IHC Status in ALK Borderline Cases
ALK IHC was performed on 13 (56%) ALK FISH bor-
derline cases for which an additional FFPE tissue section was 
available. The cytological and the very small FFPE FISH bor-
derline tumors were excluded from IHC analysis. All tested 
cases, including three borderline ALK+ and 10 borderline ALK− 
tumors, were ALK IHC negative (Supplementary Table S5, 
Supplemental Digital Content, http://links.lww.com/JTO/A763).
ALK+ control cell lines showed a very strong immuno-
reactivity in the majority of tumor cells, whereas absent or 
focal barely perceptible cytoplasmic staining was observed in 
ALK− control cell lines.
Correlation between ALK FISH Status 
and Clinicopathological Data
An ALK+ profile was significantly correlated with 
a patient age younger than 50 years (p = 0.026, two-tailed 
Fisher’s exact test). A trend was observed between female sex 
and an ALK+ profile (p = 0.068, two-tailed Fisher’s exact test).
One ALK+ tumor (#227 in Supplementary Table S3, 
Supplemental Digital Content, http://links.lww.com/JTO/
A763) had a concomitant EGFR gene mutation (deletion 
E746-A750 in exon 19).
ALK FISH Results on the Panel of Controls
In the ALK− panel of controls, cells with the ALK_R 
pattern occurred with a range of 2% to 13.3%, with a mean 
(M) ALK_R population of 6.3% and an SD of 2.9%, resulting 
in a cutoff level (M + 3 SDs) of 14.9%.
All the split patterns were observed in ALK_R cells but 
with different frequencies: ALK_S ranged from 1% to 9.3%, 
ALK_L ranged from 0% to 3.6%, ALK_FA ranged from 0% 
to 0.9%, and ALK_D ranged from 0% to 4.4% (see Fig. 5 
and Supplementary Table S8, Supplemental Digital Content, 
http://links.lww.com/JTO/A763).
The short split pattern was the most prevalent pattern 
observed in all except one controls (98%; a prevalent pattern 
was not assessable for three cases that showed split populations 
with similar frequencies, Supplementary Tables S8 and S9, 
Supplemental Digital Content, http://links.lww.com/JTO/A763).
No differences were observed in terms of prevalent 
split type between ALK− controls and borderline ALK− sam-
ples (p = 0.17), whereas a significant difference was found 
when we compared the prevalence of short split between 
ALK− controls and borderline ALK+ patients (p = 1.5 × 10−5) 
(Table 1 and Supplementary Table S10, Supplemental 
Digital Content, http://links.lww.com/JTO/A763, for raw 
data correlations).
DISCUSSION
Currently, the ALK FISH test has become manda-
tory in patients affected by lung ADCs to select the optimal 
TABLE 1.   Split Patterns Distribution and Comparison in 
Different Classes of ADC Patients and ALK Negative Controls
Prevalent Split Pattern
pShort Nonshort
ALK+ (n = 28) 8 20 5 × 10−8
ALK− (n = 187a) 152 35
Frank ALK+ (n = 22) 7 15 6.1 × 10−6
Frank ALK− (n = 170a) 137 33
Borderline ALK+ (n = 6) 1 5 3.4 × 10−3
Borderline ALK− (n = 17) 15 2
Borderline ALK+ (n = 6) 1 5 0.64
Frank ALK+ (n = 22) 7 15
Borderline ALK− (n = 17) 15 2 0.74
Frank ALK− (n = 170a) 137 33
Borderline ALK+ (n = 6) 1 5 1.5 × 10−5
Negative controls (n = 45a) 44 1
Borderline ALK− (n = 17) 15 2 0.17
Negative controls (n = 45a) 44 1
aCases for which a prevalent split pattern was assessable.
ALK, anaplastic lymphoma kinase; ADC, adenocarcinoma; ALK+ = cases with 
ALK_R cells ≥15%; ALK− = cases with ALK_R cells <15%; frank ALK+ = cases 
with ALK_R cells >20%; frank ALK− = cases with ALK_R cells <10%; borderline 
ALK+ = cases with ALK_R cells 15–20%; borderline ALK− = cases with ALK_R cells 
10–15%. p values obtained by two-tailed Fisher’s exact test.
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treatment. However, the rapid request to implement this test, 
combined with the peculiar features related to both the ALK 
FISH approach and the clinicomorphological characteristics 
of the investigated tumors, have concerned the operators.
In contrast to the break-apart/split-signal patterns that we 
are used to observe in FISH assays for the routine assessment 
of diseases such as lymphomas (e.g., MYC and BCL6 probes) 
and sarcomas (e.g., EWSR1), the ALK FISH patterns in ADCs 
are variable and difficult to interpret due to the types of gene 
rearrangements. In lung cancer, a small (12 Mb) paracentric 
inversion involving the ALK and EML4 genes causes a short 
gap between the red and green signals (split pattern) which 
is difficult to measure using a fluorescent microscope. Thus, 
we tried to quantify signals’ measures and split dimensions by 
using a digital tool for image analysis (Bioview Duet System) 
on selected samples of lung ADCs (Fig. 6). Preliminary results 
have revealed that the dimensions of ALK normal allele (fused 
signals) are generally similar among the different nuclei and 
in the range of approximately 0.7 to 1 microns. In contrast, 
the dimension of single red and single green signals is more 
variable and in the range of 0.3 to 0.8 microns; interestingly, 
single signals may have similar dimensions (Fig. 6B and D) or 
one signal can be larger than the other (Fig. 6A and C). The 
split length may approximately vary from 0.8 to 4 microns in 
case of ALK inversion/intrachromosomal translocation and to 
more than 8 microns in case of extrachromosomal transloca-
tion. Excluding this last situation, characterized by a very long 
split that is rarely the result of artifacts, the short or long split 
may be sometimes hard to distinguish from background noise 
and true split may be misestimated (see examples of mislead-
ing short split patterns in Fig. 6).
Reasons for variations occurring between single signals 
or between different splits are principally related to nuclear 
features, such as the grade of chromatin condensation/decon-
densation, DNA stretching, or the three-dimensional position 
of the signal, as well described in a recent study.26 Also, spe-
cific characteristics of the tissue as a whole (such as fixation) 
or those related to sampling procedures may further induce 
artifacts and complicate the FISH signal interpretation: DNA 
mechanical damage might induce modifications in the shape 
of the nuclei, generating split patterns that mimic ALK rear-
rangements (which could be recognized if present in both 
alleles); split-signal patterns might be visualized only in a spe-
cific area (generally the edge of the biopsy); or a limited num-
ber of neoplastic cells might be available for analysis. Overall, 
for the correct ALK FISH signal interpretation, evaluation of 
the whole sample context is required.
For all these reasons, ALK FISH analysis in lung ADCs 
is a challenging task. With the aims of ensuring that operators 
are more comfortable during ALK FISH assay evaluation and 
reducing the rate of intrinsic subjectivity in ALK FISH signals 
interpretation, we developed a descriptive scoring system. 
This method subgroups ALK-rearranged cells on the basis of 
the FISH pattern observed, as short split (ALK_S), long split 
(ALK_L), far-away split (ALK_FA), and deleted (ALK_D).
Although the far-away and deleted patterns are easier 
to recognize, the most problematic are the short and long 
split patterns, which, as mentioned before, may produce 
unconvincing results, especially when attempting to calculate 
the dimension of the spot to indicate if their distance corre-
sponds to 2 or greater diameters, as indicated by international 
recommendations.17
As a starting point, we tested this scoring system among 
three independent operators and with two different types of 
ALK FISH probes using the break-apart/split-signal strategy 
(by Abbott and Dako, respectively). In both conditions, high 
concordance was obtained in terms of not only the detection 
of ALK_R populations as a whole but also, most importantly, 
in the different FISH pattern subclasses, especially those that 
are more critical to evaluate, such as the short and long splits.
In this study, we investigated 244 lung ADC specimens 
collected from three different Institutions. ALK FISH was 
evaluable in 232 cases. The lack of tumor content, poor nuclei 
quality and/or quantity, and suboptimal time and/or type of 
fixation were the principal reasons for FISH inefficiency.
Using cutoff criteria from the literature (i.e., ALK_R cells 
≥15%), we found 12% ALK+ ADCs, with similar frequencies 
among the three Institutions. These results are in line with recent 
European and American studies on advanced lung ADCs.2,20,21,27
ALK+ patients were younger and predominantly female, in 
agreement with previous reports.16 The ALK+ profile was found 
among FFPE, biopsy, and cytological samples, indicating that 
all these samples are suitable for FISH analysis. In particular, 
the efficiency of FISH on cytological smears destained after rou-
tine Papanicolaou staining may represent a possibility for those 
patients for whom further sampling is not possible/accessible.28
The majority (71%) of ALK+ patients showed a preva-
lent nonshort split pattern, differing in a relevant way from 
ALK− patients, where the short split pattern was the most 
common (p = 5 × 10−8).
The threshold value to define a patient as ALK+, and 
therefore as eligible for crizotinib, is a major critical point for 
the ALK FISH test. Initially, the cutoff point to distinguish true 
ALK+ cells from the technical background noise was set at 15% 
after the observation that ALK+ patients (i.e., those responding 
FIGURE 5. ALK FISH patterns distribution in ALK− controls 
(n = 48); here, the presence of ALK_R cells indicates that the 
background noise is assay related. ALK_R: ALK-rearranged 
cells (namely all cells with positive patterns, constituted by 
ALK_S+ALK_L+ALK_FA+ALK_D); ALK_S: ALK+ cells with a 
short split; ALK_L: ALK+ cells with a long split; ALK_FA: ALK+ 
cells with a far-away split; ALK_D: ALK+ cells with a deleted 
pattern. ALK, anaplastic lymphoma kinase; FISH, fluorescence 
in situ hybridization.
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to crizotinib) showed a percentage of ALK_R cells ranging from 
22% to 87%, whereas true ALK− patients and controls showed a 
percentage of ALK_R cells in up to 11% of cells.14,20 However, 
as recently revealed in a larger series and as demonstrated in 
our cohort, a clear gap between ALK+ and ALK− cases does not 
seem to exist; the frequency of ALK_R cells is a continuum.21
To evaluate how the technical aspects and limits of the 
ALK FISH break-apart assay impact the threshold definition, 
we quantified the presence of ALK_R cells in a panel of con-
trols. The panel of controls was realized by using commer-
cial slides of standardized ALK negative cell lines prepared 
as cell blocks. Although bearing some differences with tissue 
mainly related to the nuclear overlap, cell blocks could repre-
sent a valid strategy to evaluate assay-dependent background 
noise because they undergo the same proceedings as lung 
specimens (i.e., both are FFPE sections) and therefore suffer 
from the same artifacts that cause false-positive cells. In this 
control series, we observed that the median rate of ALK_R 
false-positive cells was 6.3%, with an SD of 2.9%, thus giv-
ing a cutoff level (M + 3 SD) of 14.9% (Supplementary Table 
S8, Supplemental Digital Content, http://links.lww.com/JTO/
A763). Applying this threshold in practice, if the investigated 
sample contains more than this percentage of ALK_R cells, we 
may be 99.9% confident that the patient is ALK+. Interestingly, 
the cutoff value obtained in this study agrees with the liter-
ature-recommended cutoff (14.9% versus 15%), supporting 
with technical data that this value, which was set on descriptive 
evidence, is effective and sufficient to overcome technical bias.
Furthermore, our results revealed that the short split 
pattern, being observed as the prevalent type in almost all 
(98%) the investigated negative controls, was the principal 
reason responsible of the high rate of false-positive ALK_R 
cells; in contrast, nonshort split pattern (i.e., signals separated 
by long or very long distances or with a deletion) contributes 
minimally to the false-positivity rate and was rarely observed 
in controls. This short split pattern is most likely related to 
technical aspects, and we recently observed that in automated 
FISH experiments, where technical conditions were more 
controlled, the rate of the short split pattern was dramatically 
decreased (data not shown).
In this study, we identified a subgroup of 23 patients 
(10%) with a rate of ALK_R cells around the cutoff value 
(15% ± 5%), confirming the recent results of a large study.21 
The question of borderline patients is the second critical issue 
that may be encountered with the daily use of the ALK FISH 
test. This issue directly affects patients management with a 
really important rebound (i.e., the undertreatment of false-
negative patients and overtreatment of false-positive ones).
FIGURE 6. A–D, Photographic gal-
lery of lung cancer cells carrying ALK 
FISH short split patterns. For each cell 
is reported the approximate measure 
of fused signals, single signals, and 
split length, realized by the Bioview 
Duet System. ALK, anaplastic lym-
phoma kinase; FISH, fluorescence in 
situ hybridization.
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By applying our detailed scoring system, we found 
significant differences (p = 3.4 × 10−3) in borderline patients: 
the nonshort split pattern was peculiar of borderline ALK+ 
(similarly to frank ALK+), whereas the short split pattern was 
characteristic of borderline ALK− (similarly to frank ALK− 
patients and controls).
These observations could be used at practical level to 
distinguish a real borderline-positive patient from a false-
positive one. Moreover, in equivocal cases, the presence of 
long, far-away, and deleted split patterns, even if barely over 
the threshold, could reflect the presence of a rearrangement 
and not a technical bias.
This claim is also supported by recent studies indicating 
that the percentage of ALK_R-positive cells is not correlated 
with effective crizotinib therapy in ALK+ patients.2 Nevertheless, 
the biological meaning of these borderline patients requires fur-
ther investigation. The use of IHC as an alternative method of 
ALK investigation has been proposed, but some concerns still 
remain on this borderline category, as recently emerged29,30 and 
as observed in our study (no immunoreactivity in both border-
line-positive and borderline-negative case).
ALK test is challenging. The ALK FISH pattern scoring 
system should be used to better classify lung ADCs as eligible 
for therapy. In particular, the evaluation of borderline cases 
(15% ± 5%), in which even IHC may be ineffective, could 
strongly benefit from the detailed analysis of split types, dis-
tinguishing between short and nonshort patterns.
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